Management of Atrial Flutter in Pregnancy

Initial Assessment and Management

The European Society of Cardiology recommends immediate electrical cardioversion as the first-line treatment for atrial flutter in a pregnant woman with stable vitals to restore sinus rhythm and prevent maternal and fetal hemodynamic compromise 1, 2, 3
Atrial flutter during pregnancy is rare and typically associated with structural heart disease or hyperthyroidism, which should be investigated as first priorities, according to the European Heart Journal 2, 3
Hemodynamic status evaluation is crucial, as atrial flutter can lead to serious hemodynamic consequences for both mother and fetus due to rapid ventricular response, as stated by the European Heart Journal 2, 3

For durations less than 48 hours with no risk factors, the European Heart Journal recommends administering IV heparin or weight-adjusted therapeutic dose LMWH pericardioversion 2
For durations of 48 hours or more, or unknown duration, anticoagulation with LMWH for at least 3 weeks before elective cardioversion is recommended by the European Heart Journal 2, 3
The European Heart Journal also suggests continuing anticoagulation for at least 4 weeks post-cardioversion due to the risk of thromboembolism from "atrial stunning" 2, 3

The European Heart Journal recommends selective beta-1 blockers, such as metoprolol, as the first-line treatment for rate control in atrial flutter during pregnancy 1, 3
Digoxin may be used as a second-line treatment for ventricular rate control if beta-blockers are ineffective or contraindicated, according to the European Heart Journal 1, 3
IV ibutilide or flecainide may be considered for pharmacological termination in hemodynamically stable patients, as recommended by the European Heart Journal 2, 3

The European Heart Journal suggests considering prophylactic antiarrhythmic therapy if symptoms are intolerable or if there is a risk of recurrence, with first-line options including digoxin or selective beta-blockers like metoprolol 1, 3
Anticoagulation should be continued based on thromboembolic risk factors using LMWH during pregnancy, as recommended by the European Heart Journal 2, 3
Prompt intervention is crucial, even with stable vitals, as atrial flutter can rapidly deteriorate and affect fetal wellbeing, according to the European Heart Journal 2
The European Heart Journal also emphasizes the importance of avoiding amiodarone unless absolutely necessary due to its fetotoxic effects 1, 2, 3